Project Grant R01DK142414
Award Date
9/19/24
Completion Date
6/30/29
Dollars Obligated
$562K
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
This $698,646 federal Project Grant was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant aims to study the functional and disease relevance of distinct pancreatic beta-cell subtypes, with a focus on understanding their epigenetic regulation and relationship to type 2 diabetes (T2D). The research will use novel single-cell epigenomic tools, conditional...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) provides $194,616 to Weill Medical College of Cornell University to investigate the impact of activating the transcription factor ATF6 in pancreatic beta cells. The research aims to examine how constitutive activation of ATF6 affects insulin production and secretion in beta cells,...
This $2,155,558 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support a translational research project at the Joslin Diabetes Center, Inc. to investigate the mechanisms by which glucose toxicity alters the regulation of insulin biosynthesis and secretion in pancreatic beta cells. The research aims to elucidate how chronic exposure to high...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is providing $1,946,207 to The Leland Stanford Junior University to generate comprehensive maps of variant effects for genes involved in monogenic diabetes. The overarching goal is to enable precision diagnostics and precision medicine for diabetes, a global health challenge affecting...
This federal Project Grant award of $444,867.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the role of the UPR transducer XBP1 in pancreatic beta cell survival and function under metabolic stress. The research will use a novel mouse model to elucidate the pathological role of XBP1s in beta cell integrity under metabolic stress, in order to...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,331,148 to Yale University to investigate the mechanisms by which pancreatic alpha cells compensate for beta cell mass deficiency in type 2 diabetes. The research aims to determine the signaling pathways and adaptations that allow alpha cells to increase glucagon secretion in a...
This federal Project Grant award of $568,075.00, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to determine the role of the NR4A1 gene in pathways that can expand functional beta-cell mass as a potential treatment for type 1 and type 2 diabetes. The research aims to: 1) examine the effect of NR4A1 in GLP-1R and DYRK1A mediated beta-cell mass...
This federal Project Grant award, valued at $567,643.00 and spanning September 2024 through May 2029, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research at Duke University focused on understanding the communication between alpha and beta cells, and its role in insulin secretion and glucose homeostasis, particularly in the context of...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $575,394 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The 5-year grant, commencing on August 1, 2024, will support research to develop a multi-ancestry polygenic risk score for predicting type 1 diabetes (T1D) and related immune-mediated forms of diabetes....
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $823,473 Cooperative Agreement under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The General Hospital Corporation (Massachusetts General Hospital) to study longitudinal omics-based trajectories of type 2 diabetes subtypes. The five-year project aims to use multi-omic data to refine definitions of prediabetes and type 2 diabetes, describe associations between...